Company Encyclopedia
View More
name
CHAOJU EYE CARE
02219.HK
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, myopia prevention and control, dry eye syndrome, and oculoplastic, as well as optical products and services. The company also provides treatment for eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases, and pediatric eye diseases. In addition, it offers Amblyopia recovery services; and sells eyewear, equipment, and optical products.
33.11 B
02219.HKMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
C
Health Care FacilitiesIndustry
Industry Ranking6/18
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.36%B
    • Profit Margin12.58%B
    • Gross Margin42.63%B
  • Growth ScoreD
    • Revenue YoY-2.81%D
    • Net Profit YoY-19.66%D
    • Total Assets YoY7.78%B
    • Net Assets YoY2.77%C
  • Cash ScoreC
    • Cash Flow Margin794.95%B
    • OCF YoY-2.81%D
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreA
    • Gearing Ratio21.28%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chaoju Eye Care Announces HK$50 Million Share Repurchase Plan

    Chaoju Eye Care Holdings Ltd. announced a share repurchase plan of up to HK$50 million, indicating confidence in its business outlook and aiming to enhance shareholder value. This strategic move is subject to market conditions and regulatory compliance. The company operates in the eye care industry, providing services and products, and is incorporated in the Cayman Islands. The latest analyst rating for its stock is 'Hold' with a HK$3.00 price target.

    Tip Ranks·
    HK
    02219
    +1.83%
    Tip Ranks·
    HK
    02219
    +1.83%

    Chaoju Eye Care Expands Investment in BOC Wealth Management Products

    Chaoju Eye Care Holdings Ltd. (HK:2219) announced that its subsidiary, Chaoju Medical Technology, has subscribed to BOC wealth management products worth RMB240 million, funded by surplus cash. This transaction is classified as a discloseable transaction under Hong Kong Stock Exchange rules and is expected to influence the company's financial strategy and cash management practices. The latest analyst rating for HK:2219 is a Hold with a price target of HK$3.00. Chaoju Eye Care operates in the eye care industry and has a market cap of HK$1.9B.

    Tip Ranks·
    HK
    02219
    +1.83%
    Tip Ranks·
    HK
    02219
    +1.83%

    The total subscription principal amount of CHAOJU EYE CARE's affiliated financial products is 240 million yuan

    According to the Zhitong Finance APP, CHAOJU EYE CARE announced that on September 26, 2025, CHAOJU Medical Technology (the company's indirect wholly-owned subsidiary) will further subscribe to a total principal amount of RMB 240 million in Bank of China wealth management products

    Zhitong·
    HK
    02219
    +1.83%
    Zhitong·
    HK
    02219
    +1.83%

    Chaoju Eye Care Holdings Ltd. Reports 4.9% Decline in Revenue and 17.1% Drop in Net Profit for First Half of 2025

    Chaoju Eye Care Holdings Ltd. reported a 4.9% decline in revenue to RMB698.3 million and a 17.1% drop in net profit to RMB110.7 million for the first half of 2025. The non-IFRS adjusted net profit also fell to RMB118.4 million, with a margin decrease to 17.0%. Cash and cash equivalents decreased significantly to RMB283.8 million. Total assets rose to RMB3.00 billion, while total liabilities increased to RMB638.5 million. The company is focusing on enhancing corporate governance and expanding AI use for efficiency improvements.

    Reuters·
    HK
    02219
    +1.83%
    Reuters·
    HK
    02219
    +1.83%

    CICC: Maintain CHAOJU EYE CARE outperform industry rating, target price HKD 3.9

    CICC maintains a "Outperform" rating on CHAOJU EYE CARE, with a target price of HKD 3.90, and expects EPS of HKD 0.28 and HKD 0.30 for 2025 and 2026, respectively. Although revenue in 1H25 decreased by 4.9% to HKD 698 million, and net profit attributable to the parent company fell by 16.7%, the company's refractive surgery prices are expected to increase, and the promotion of new technologies will enhance market competitiveness. Overall, while outpatient and inpatient volumes have declined, the proportion of revenue from consumer ophthalmic services remains high

    Zhitong·
    HK
    02219
    +1.83%
    Zhitong·
    HK
    02219
    +1.83%
    © 2025 Longbridge｜Disclaimer